Our top pick for
Amgen Inc is a drug manufacturers—general business based in the US. Amgen shares (AMGN) are listed on the NASDAQ and all prices are listed in US Dollars. Amgen employs 23,400 staff and has a trailing 12-month revenue of around USD$24.3 billion.
Since the stock market crash in March caused by coronavirus, Amgen's share price has had significant positive movement.
Its last market close was USD$230.71, which is 3.43% up on its pre-crash value of USD$222.79 and 30.31% up on the lowest point reached during the March crash when the shares fell as low as USD$177.05.
If you had bought USD$1,000 worth of Amgen shares at the start of February 2020, those shares would have been worth USD$857.14 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,063.57.
|Latest market close||USD$230.71|
|52-week range||USD$177.05 - USD$264.97|
|50-day moving average||USD$247.3757|
|200-day moving average||USD$237.8412|
|Wall St. target price||USD$260.79|
|Dividend yield||USD$6.4 (2.67%)|
|Earnings per share (TTM)||USD$12.241|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-10-13)||-3.61%|
|1 month (2020-09-18)||-6.87%|
|3 months (2020-07-20)||-11.59%|
|6 months (2020-04-20)||-2.49%|
|1 year (2019-10-18)||13.81%|
|2 years (2018-10-19)||14.33%|
|3 years (2017-10-20)||26.10%|
|5 years (2015-10-20)||53.35%|
Valuing Amgen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Amgen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Amgen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 20x. In other words, Amgen shares trade at around 20x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Amgen's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.5435. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Amgen's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Amgen's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$12.1 billion.
The EBITDA is a measure of a Amgen's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$24.3 billion|
|Operating margin TTM||38.06%|
|Gross profit TTM||USD$19 billion|
|Return on assets TTM||9.3%|
|Return on equity TTM||68.05%|
|Market capitalisation||USD$140.2 billion|
TTM: trailing 12 months
There are currently 6.1 million Amgen shares held short by investors – that's known as Amgen's "short interest". This figure is 9.5% down from 6.8 million last month.
There are a few different ways that this level of interest in shorting Amgen shares can be evaluated.
Amgen's "short interest ratio" (SIR) is the quantity of Amgen shares currently shorted divided by the average quantity of Amgen shares traded daily (recently around 2.7 million). Amgen's SIR currently stands at 2.24. In other words for every 100,000 Amgen shares traded daily on the market, roughly 2240 shares are currently held short.
However Amgen's short interest can also be evaluated against the total number of Amgen shares, or, against the total number of tradable Amgen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Amgen's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Amgen shares in existence, roughly 10 shares are currently held short) or 0.0105% of the tradable shares (for every 100,000 tradable Amgen shares, roughly 11 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Amgen.
Find out more about how you can short Amgen stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Amgen.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 20.95
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Amgen's overall score of 20.95 (as at 10/01/2020) is pretty good – landing it in it in the 24th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Amgen is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 1.53/100
Amgen's environmental score of 1.53 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that Amgen is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 15.13/100
Amgen's social score of 15.13 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that Amgen is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 5.8/100
Amgen's governance score puts it squarely in the 3rd percentile of companies rated in the same sector. That could suggest that Amgen is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Amgen scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Amgen has, for the most part, managed to keep its nose clean.
|Total ESG score||20.95|
|Total ESG percentile||23.7|
|Environmental score percentile||3|
|Social score percentile||3|
|Governance score percentile||3|
|Level of controversy||2|
Dividend payout ratio: 39.76% of net profits
Recently Amgen has paid out, on average, around 39.76% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.67% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Amgen shareholders could enjoy a 2.67% return on their shares, in the form of dividend payments. In Amgen's case, that would currently equate to about $6.4 per share.
While Amgen's payout ratio might seem fairly standard, it's worth remembering that Amgen may be investing much of the rest of its net profits in future growth.
Amgen's most recent dividend payout was on 8 September 2020. The latest dividend was paid out to all shareholders who bought their shares by 14 August 2020 (the "ex-dividend date").
Amgen's shares were split on a 2:1 basis on 22 November 1999. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Amgen shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Amgen shares which in turn could have impacted Amgen's share price.
Over the last 12 months, Amgen's shares have ranged in value from as little as $177.05 up to $264.97. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Amgen's is 0.8152. This would suggest that Amgen's shares are less volatile than average (for this exchange).
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Sensipar/Mimpara to treat secondary hyperparathyroidism; and EPOGEN to treat anemia caused by chronic kidney disease. It also markets other products in various markets, including Nplate, Vectibix, Repatha, Parsabiv, BLINCYTO, Aimovig, NEUPOGEN, Otezla, AMGEVITA, KANJINTI, EVENITY, IMLYGIC, MVASI, and Corlanor. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; QIAGEN N.V.; Adaptive Biotechnologies; and Eli Lilly and Company. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.